Longevity Is a Venture, Not a Service Line
About Event
In this one-hour session, we explain what a longevity venture is, what it is not, and the four ways these builds fail before opening.
Boards across the GCC are asking about longevity. In most rooms, no one can yet say precisely what is proposed: a clinic, a service line, a wellness offer, or a business. This hour separates them.
Dr. Ana Baroni explains what changes clinically when the goal shifts from treating what is broken to measuring a person's reserve capacity. Kamal Hassan then addresses what actually kills these builds. The failure of a new longevity clinic is rarely clinical. It is structural.
We then focus on the layer most plans defer. Between two clinic visits a year, something must hold both the relationship and the measurement. Almost every plan treats this as phase two. The useful questions are not technical. What should a venture buy, and what must it own? Where does defensibility sit once a member can legally take their record? And what does it cost, at the first capital gate, to discover that architecture built for thirty members cannot carry three thousand?
We close on the operator landscape as it stands, drawn from published information, and on the difference between a model that produces churn and one that produces an asset.
We present this together because that is how the work is done. Clinical authority and operating authority sit on the same venture team from day one. The two failure modes in this category, clinical under-credentialing and operational under-governance, explain why.
By the end of the session, you will be able to:
Distinguish lifespan, healthspan, and peakspan, and explain why the gap between the first two defines the business. Recent decades added roughly two years of life but only about nine months of healthy life. Closing that gap is the category.
Identify the four patterns that sink longevity builds before they open.
Separate what a longevity platform should buy from what it has to own, and explain why the second is the asset while the first is a purchase order.
Recognize two platform claims that do not survive investor diligence, and know what to say instead.
Judge whether what your organization is planning is a venture or a department.
The hour
0:00 The question your board is actually asking and a live poll on where your organization stands
0:05 Lifespan, healthspan, peakspan: why the gap is the business
0:11 What changes clinically: reserve capacity, baselines, and dosing against them
0:17 The four failure patterns, and the operator landscape as it stands
0:30 The digital layer: what you buy, what you own, and what a rewrite costs
0:40 A joint exercise: three questions we put to you
0:47 Open discussion and next steps
Who it's for
Hospital and health group leadership, hospitality groups, sports institutions, family office principals, insurers and corporates, and board and investment committee members. Clinicians are welcome, and the session is designed so you will not be lost, though the lens is commercial.
Your hosts
Kamal Hassan, Founder and Managing Partner of TURN8 and Strategic Operating Partner on every TURN8 Longevity build. Since 2013, TURN8 has built more than 120 ventures and deployed over 500 million dollars across CVC platforms, funds, and syndicates. On a longevity build, he leads business model development, validation, governance, and capitalization.
Dr. Ana Baroni, Medical Strategy & Clinical Leadership at TURN8 and General Secretary of the International Advisory Board at the Asia-Pacific Longevity Medicine Society. MD and PhD in Molecular Diagnostics, cum laude, with more than 27 years of clinical practice across precision, regenerative, functional and integrative medicine. On every TURN8 Longevity build, she serves as Medical Director, with final authority on clinical protocols and quality standards, evidence-tier classification, and clinical performance measures.
Practical notes
Attendance is free. A recording will typically be shared after the session, and attendees may request a complimentary institutional readiness assessment review.